Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy

Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10–20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to immunotherapy intervention. We report that very low tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Gromeier, Matthias, Brown, Michael C., Zhang, Gao, Lin, Xiang, Chen, Yeqing, Wei, Zhi, Beaubier, Nike, Yan, Hai, He, Yiping, Desjardins, Annick, Herndon, James E., Varn, Frederick S., Verhaak, Roel G., Zhao, Junfei, Bolognesi, Dani P., Friedman, Allan H., Friedman, Henry S., McSherry, Frances, Muscat, Andrea M., Lipp, Eric S., Nair, Smita K., Khasraw, Mustafa, Peters, Katherine B., Randazzo, Dina, Sampson, John H., McLendon, Roger E., Bigner, Darell D., Ashley, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806846/
https://www.ncbi.nlm.nih.gov/pubmed/33441554
http://dx.doi.org/10.1038/s41467-020-20469-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806846/
https://www.ncbi.nlm.nih.gov/pubmed/33441554
http://dx.doi.org/10.1038/s41467-020-20469-6

Ejemplares similares